An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.
Age range
30 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Determine the impact of platelet FcγRIIa expression on 1-year risk of recurrent stroke in ICAD.
Timeframe: 1 year
Quantify the impact of WSS from CTA CFD on 1-year risk of recurrent stroke in ICAD
Timeframe: 1 year
Develop a precision model to determine the risk of recurrent stroke 1 year after index events due to ICAD based on individual FcγRIIa expression and WSS from baseline CTA.
Timeframe: 1 year